Developing therapeutics for the treatment of multiple sclerosis

NeuroRx

Volumn 2, Issue 4, 2005, Pages 638-649

  Virley, David J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Demyelination; Experimental autoimmune encephalomyelitis; Inflammation; Multiple sclerosis; Regeneration; Therapeutics

Indexed keywords

3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; ALPHA4 INTEGRIN; BETA1A INTERFERON; BIO 5192; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; CT 301; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FINGOLIMOD; FLECAINIDE; GLATIRAMER; IMMUNOLOGIC AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MIFEPRISTONE; MITOXANTRONE; NATALIZUMAB; PEPTIDE ANTIBODY; PHENIDONE; PIROXICAM; RECOMBINANT SOMATOMEDIN C; SPHINGOSINE 1 PHOSPHATE RECEPTOR; TACROLIMUS; TBC 3486; UNCLASSIFIED DRUG;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DEPRESSION; DISABILITY; DISEASE COURSE; DRUG RESEARCH; DRUG SAFETY; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE REACTION; LIVER TOXICITY; MENSTRUATION DISORDER; MOOD DISORDER; MULTIPLE SCLEROSIS; MYALGIA; NEPHROTOXICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; ONSET AGE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; STOMACH PAIN; SUICIDAL BEHAVIOR;

EID: 25844490953     PISSN: 15455343     EISSN: 15455351     Source Type: Journal    
DOI: 10.1602/neurorx.2.4.638     Document Type: Article

References (80)

1. Wingerchuk DM, Lucchinetti CF, Noseworthy JH. Multiple Sclerosis: current pathophysiological concepts. Lab Invest 81:263-281, 2001.
2. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded Disability Status Scale (EDSS). Neurology 33:1444-1452, 1983.
3. Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler 5:244-250, 1999.
4. Patzold T, Schwengelbeck M, Ossege LM, Malin JP, Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 105:164-168, 2002.
5. Kalkers NF, Bergers L, de Groot V, Lazeron RHC, van Walderveen MAA, Uitdehaag BMJ, et al. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 56:215-219, 2001.
6. Gijbels K, Engelborghs S, De Deyn PP. Experimental autoimmune encephalomyelitis: an animal model for multiple sclerosis. Neurosci Res Commun 26:193-206, 2000.
7. Juedes AE, Hjelmstrom P, Bergman CM, Neid AL, Ruddle NH. Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol 164:419-426, 2000.
8. Linthicum DS. Development of acute autoimmune encephalomyelitis in mice: factors regulating the effector phase of the disease. Immunobiology 162:211-220, 1982.
9. Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells. J Immunol 169:117-125, 2002.
10. Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol 28:261-270, 1990.
11. g7) mice share an amino acid motif. J Immunol 156:3000-3008, 1996.
12. Smith PA, Heijmans N, Ouwerling B, Breij EC, Evans N, van Noort JM, et al. Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice. Eur J Immunol 35:1311-1319, 2005.
13. Buddeberg BS, Kerschensteiner M, Merkler D, Stadelmann C, Schwab ME. Behavioral testing strategies in a localized animal model of multiple sclerosis. J Neuroimmunol 153:158-170, 2004.
14. 't Hart BA, van Meurs M, Brok HPM, Massacesi L, Bauer J, Boon L, et al. A new primate model for multiple sclerosis in the common marmoset. Immunol Today 21:290-297, 2000.
15. 't Hart BA, Vogels J, Bauer J, Brok HPM, Blezer E. Non-invasive measurement of brain damage in a primate model of multiple sclerosis. Trends Mol Med 10:85-91, 2004.
16. 't Hart BA, Blezer ELA, Brok HPM, Boon L, de Boer M, Bauer J et al. Treatment with chimeric anti-human CD40 antibody suppresses MRI-detectable inflammation and enlargement of pre-existing brain lesions in common marmosets affected by MOG-induced EAE. J Neuroimmunol 163:31-39, 2005.
17. Neuhaus O, Kieseier BC, Hartung HP. Mechanisms of mixoxantitrone in multiple sclerosis-what is known? J Neurol Sci 223:25-27, 2004.
18. Pozzilli C, Marinelli F, Romano S, Bagnato F. Corticosteroids treatment. J Neurol Sci 223:47-51, 2004.
19. Bolton C, Flower RJ. The effects of the anti-glucocorticoid RU38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci 45:97-104, 1989.
20. Bolton C, Oneill JK, Allen SJ. Baker D. Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids. Int Arch Allergy Immunol 114:74-80, 1997.
21. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon-β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J Neuroimmunol 64:91-100, 1996.
22. Tuohy VK, Yu M, Yin L, Mathisen PM. Johnson JM, Kawczak JA. Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J Neuroimmunol 111:55-63, 2000.
23. The IFNβ Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661, 1993.
24. The IFNβ Multiple Sclerosis Study Group and the University of British Columba MS/MRI Analysis Group. Interferon β-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45:1277-1285, 1995.
25. Paty DW, Li DK, University of British Columbia MS/MRI study Group and the IFNβ Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43:662-667, 1993.
26. Teitelbaum D, Arnon R, Sela M. Copolymer 1: from basic research to clinical application. Cell Mol Life Sci 53:24-28, 1997.
27. Bornstein MB, Miller A, Slagle S. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl. J Med 317:408-414, 1987.
28. Johnson KP, Brooks BR, Cohen JA. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of phase III multicenter, double blind, placebo-controlled trial. Neurology 45:1268-1276, 1995.
29. Mancardi GL, Sardanelli F, Parodi RC, Melani E, Capello E, Inglese M, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 50:1127-1133, 1998.
30. Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol 109:1321-1330, 1989.
31. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 60:577-584, 1990.
32. Baron JL, Madri JA, Ruddle NH, Hashim G, Janeway CA Jr. Surface expression of α4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 177:57-68, 1993.
33. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against α4 β1 integrin. Nature 356:63-66, 1992.
34. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Horner HC. A monoclonal antibody to α4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 58:1-10, 1995.
35. Theien BE, Vanderlugt CL, Eagar TN, Nickerson-Nutter C, Nazareno R, Kuchroo VK, et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J Clin Invest 107:995-1006, 2001.
36. Dutta AS, Gormley JJ, Coath M, Hassall L, Hayward CF, Gellert PR et al. Potent cyclic peptide inhibitors of VLA-4 (α4β1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation. J Pept Sci 6:398-412, 2000.
37. van der Laan LJW, van der Goes A, Wauben MHM, Ruuls SR, Döpp EA, De Groot CJA, et al. Beneficial effect of modified peptide inhibitor of α4 integrins on experimental allergic encephalomyelitis in Lewis rats. J Neurosci Res 67:191-199, 2002.
38. Vajkoczy P, Laschinger M, Engelhardt B. α4-Integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 108:557-565, 2001.
39. Graesser D, Mahooti S, Madri JA. Distinct roles for matrix metalloproteinase-2 and α4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J Neuroimmunol 109:121-131, 2000.
40. Piraino PS, Yednock TA, Freedman SB, Messersmith EK, Pleiss, MA, Vandevert C, et al. Prolonged reversal of chronic experimental allergic encephalomyelitis using a small molecule inhibitor of α4 integrin. J Neuroimmunol 131:147-159, 2002.
41. Cannella B, Gaupp S, Tilton RG, Raine CS. Differential efficacy of a synthetic antagonist of VLA-4 during the course of chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res 71:407-416, 2003.
42. Leone DR, Giza K, Gill A, Dolinski BM, Yang W, Perper S, et al. An assessment of the mechanistic differences between two integrin α(4)β(1) inhibitors, the monoclonal antibody TA-2 and the small molecule BI05192, in rat experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther 305:1150-1162, 2003.
43. Pepinsky RB, Lee WC, Cornebise M, Gill A, Wortham K, Chen LL. et al. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule of integrin α4β1 with improved pharmaceutical properties. J Pharmacol Exp Ther 312:742-750, 2005.
44. Elovaara I, Ukkonen M, Leppakynnas M, Lehtimaki T, Luomala M, Peltola J, et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol 57:546-551, 2000.
45. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, et al. The International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of Natalizumab for relapsing multiple sclerosis. N Eng J Med 348:15-23, 2003.
46. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, et al. The effect of anti-α4 integrin antibody on brain lesion activity in MS. Neurology 53:466-472, 1999.
47. Rice GPA, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis-mechanisms and rationale. Neurology 64:1336-1342, 2005.
48. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: Natalizumab. Nat Rev Drug Disc 4:510-518, 2005
49. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med (10.1056/NEJMc055235), 9 June 2005.
50. Gonsette RE. New immunosuppressants with potential implication in multiple sclerosis. J Neurol Sci 223:87-93, 2004.
51. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther 305:70-77, 2003
52. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 20:16-24, 2004.
53. Multiple sclerosis-FTY720, a novel once-daily oral medication, shows promising results. Medical News Today. Available at www. medicalnewstoday.com. Accessed July 4, 2005.
54. O'Banion MK. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 13:45-82, 1999.
55. Nogawa S, Zhang FY, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755, 1997.
56. Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol (Berl) 98:9-14, 1999.
57. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord-implications for therapy. Neurology 57:952-956, 2001.
58. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol 58:487-492, 2001.
59. Deininger MH, Schluesener HJ. Cyclooxygenases-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol 95:202-208, 1999.
60. Moon C, Alm M, Wie MB, Kim HM, Koh CS, Hong SC, et al. Phenidone. a dual inhibitor of cyclooxygenases and lipoxygenases, ameliorates rat paralysis in experimental autoimmune encephalomyelitis by suppressing its target enzymes. Brain Res 1035:206-210, 2005.
61. Rose JW, Hill KE, Watt HE, Carlson NG. Inflammatory cell expression of cyclooxygenase-2 in the multiple sclerosis lesion. J Neuroimmunol 149:40-49, 2004.
62. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 63:901-910, 2004.
63. Weber F, Hempel K. Protection against experimental allergic encephalomyelitis with complete Freund's adjuvant is unaffected by prostaglandin synthesis inhibition. Int Arch Allergy Appl Immunol 89:242-245, 1989.
64. Simmons RD, Hugh AR, Willenborg DO, Cowden WB. Suppression of active but not passive autoimmune encephalomyelitis by dual cyclo-oxygenase and 5-lipoxygenase inhibition. Acta Neurol Scand 85:197-199, 1992.
65. Merlin J, Stackpoole A. Anti-PGE antibodies inhibit in vivo development of cell-mediated immunity. Nature 294:456-458, 1981.
66. Stangel, M. Remyelinating and neuroprotective treatments in multiple sclerosis. Expert Opin Investig Drugs 13:331-347, 2004.
67. Lubetzki C, Williams A, Stankoff B. Promoting repair in multiple sclerosis: problems and prospects. Curr Opin Neurol 18:237-244, 2005.
68. Bechtold DA, Kapoor R, Smith KJ. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607-616, 2004.
69. Fontoura P, Ho PP, DeVoss J, Zheng BH, Lee BJ, Kidd BA, et al. Immunity to the extracellular domain of Nogo-A modulates experimental autoimmune encephalomyelitis. J Immunol 173:6981-6992, 2004.
70. Karnezis T, Mandemakers W, McQualter JL, Zheng BH, Ho PP, Jordan KA, et al. The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nat Neurosci 7:736-744, 2004.
71. Frank JA, Richert N, Lewis B. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sclerosis patients. Mult Scler 8:24-29, 2002.
72. Pluchino S, Quattrini A, Brambilla E, Gritti A, Salani G, Dina G. Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis. Nature 422:688-693, 2003.
73. Kappos L, Kuhle J, Gass A, Achtnichts L, Radue EW. Alternatives to current disease-modifying treatment in MS: what do we need and what can we expect in the future? J Neurol 251 [Suppl 5]:57-64, 2004.
74. Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 127:1463-1478, 2004.
75. Anderson SA, Shukaliak-Quandt J, Jordan EK, Arbab AS, Martin R, McFarland H, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol 55:654-659, 2004.
76. Clark CA, Werring DJ. Diffusion tensor imaging in spinal cord: methods and applications-a review. NMR Biomed 15:578-586, 2002.
77. Ibrahim SM, Gold R. Genomics, proteomics, metabolomics: what is in a word for multiple sclerosis? Curr Opin Neurol 18:231-235, 2005.
78. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508, 2002.
79. Ibrahim SM, Mix E, Bottcher T, Koczan D, Gold R, Rolfs A, et al. Gene expression profiling of the nervous system in murine experimental autoimmune encephalomyelitis. Brain 124:1927-1938, 2001.
80. Ryan J, Hurko O. Translational research in central nervous system drug discovery. NeuroRx 2:671-682, 2005.